One potential approach to achieving a functional HIV cure is to first reduce the size of the HIV reservoir and then engineer an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy. MicAbodies, comprised of full-length broadly neutralizing HIV antibodies coupled to a mutated ligand, selectively engage a mutant receptor that has been engineered as a chimeric antigen receptor (CAR) and expressed on CD8 T cells (convertibleCAR-T cells). The HIV-specific MicAbodies and the convertibleCAR-T cells can detect and eliminate HIV infected cells. The modularity of the convertibleCAR-T cell system allows multiplexing with several anti-HIV antibodies and yields greater breadth and control, thus making this platform a promising tool for attacking the latent HIV reservoir.
Creative Biolabs invited Dr. Eytan Herzig, a Staff Research Scientist in the Gladstone Center for HIV Cure Research, to share his profound insights on the principles and opportunities of innovative convertibleCAR-T platform in HIV cure.
During this webinar, the following topics were discussed:
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE